<DOC>
	<DOCNO>NCT00093821</DOCNO>
	<brief_summary>This phase I trial study side effect best dose tanespimycin treat young patient recurrent refractory leukemia select solid tumor . Drugs use chemotherapy , tanespimycin , work different way stop cancer cell divide stop grow die .</brief_summary>
	<brief_title>Tanespimycin Treating Young Patients With Recurrent Refractory Leukemia Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose ( MTD ) 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) pediatric patient recurrent refractory leukemia select solid tumor . II . Determine level key protein know influence cancer cell survival proliferation patient treat drug MTD . SECONDARY OBJECTIVES : I . Determine pharmacokinetics drug patient . II . Evaluate effect genetic polymorphism know alter activity enzymes involved metabolism drug . III . Correlate alteration fludeoxyglucose F18 accumulation tumor response patient treated drug . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord diagnosis ( leukemia v solid tumor ) . Patients receive tanespimycin IV 2-6 hour day 1 , 4 , 8 , 11 ( patient solid tumor ) OR day 1 , 4 , 8 , 11 , 15 , 18 ( patient leukemia ) . Courses patient repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tanespimycin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 15 patient treated MTD . Patients follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<criteria>Histologically confirm diagnosis 1 follow malignancy : Leukemia Lymphoid , myeloid , mixed lineage Relapsed ( second great relapse ) refractory disease , confirm 1 following : Bone marrow relapse , define either M3 bone marrow ( &gt; 25 % blast bone marrow aspirate ) OR M2 bone marrow ( 525 % blast bone marrow aspirate ) time complete remission attain CNS relapse , define least 5 WBC/mL cytospin cerebrospinal fluid ( CSF ) specimen OR le 5 WBC/mL cytospin 2 consecutive CSF specimen obtain &gt; = 4 week apart definitive confirmation blast derive original leukemic clone molecular cytogenetics , multiparameter flow cytometry , immunostaining &gt; = 2 antigens Patients underlie chronic myeloid leukemia must &gt; 25 % blast bone marrow aspirate Patients M3 bone marrow AND extramedullary site disease , leptomeningeal disease , eligible Solid tumor One follow tumor type : Neuroblastoma Ewing 's sarcoma Osteosarcoma Desmoplastic small round cell tumor Rhabdomyosarcoma Progressed prior standard therapy OR effective standard therapy exist Measurable nonmeasurable disease No known brain metastases No active leptomeningeal leukemia , define follow criterion : WBC &gt; 5/mm^3 cerebrospinal fluid ( CSF ) Unequivocal confirmation leukemic blast CSF cell morphology No symptomatic CNS disease ( e.g. , cranial nerve abnormality ) without cytologic abnormality CSF Performance status Karnofsky 70100 % ( patient &gt; 10 year age ) Performance status Lansky 70100 % ( patient = &lt; 10 year age ) More 8 week Absolute neutrophil count &gt; = 750/mm^3 Platelet count &gt; = 75,000/mm^3 ( transfusion independent ) Hemoglobin &gt; = 8.5 g/dL ( transfusion allow ) Bilirubin &lt; 1.5 mg/dL ALT AST = &lt; 2.5 time upper limit normal ( ULN ) INR = &lt; 1.5 time ULN Albumin &gt; 2.0 g/dL Creatinine = &lt; 1.5 time ULN age Creatinine clearance radioisotope glomerular filtration rate &gt; 60 mL/min Ejection fraction &gt; = 50 % Shortening fraction &gt; = 28 % QTc &lt; 450 msec men ( 470 msec woman ) No congenital long QT syndrome LVEF &gt; 40 % MUGA No symptomatic congestive heart failure No cardiac arrhythmia No New York Heart Association class III IV heart failure No myocardial infarction within past year No uncontrolled dysrhythmias No poorly control angina More 12 month since active ischemic heart disease No history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation &gt; = 3 beat row ) No left bundle branch block No significant cardiac disease No pulmonary fibrosis radiography No ongoing active bacterial fungal infection No uncontrolled illness No psychiatric illness social situation would preclude study compliance No history serious allergic reaction attribute eggs dimethyl sulfoxide Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Recovered immunotherapy At least 6 month since prior allogeneic stem cell transplantation At least 3 month since prior autologous stem cell transplantation At least 2 week since prior biologic agent ( e.g. , monoclonal antibody ) At least 1 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) Recovered prior chemotherapy At least 2 week since prior chemotherapy ( patient leukemia ) At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) ( patient solid tumor ) No prior oxaliplatin No concurrent corticosteroid except treatment adrenal crisis patient suppress hypothalamicpituitaryadrenal axis response OR treatment allergic reaction medication blood product Recovered prior radiotherapy At least 6 month since prior radiotherapy &gt; = 50 % pelvis At least 6 month since prior radiotherapy substantial bone marrow , include total body irradiation At least 4 week since prior local ( small port ) radiotherapy No prior radiotherapy heart At least 1 week since prior retinoids No concurrent antiretroviral therapy HIVpositive patient No concurrent medication control arrhythmias No concurrent medication prolong may prolong QTc interval No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>